Scarica l'app Stockscreener
9.05
5.23%
0.45
Dopo l'orario di chiusura:
9.00
-0.05
-0.55%
Cartesian Therapeutics Inc Borsa (RNAC) Ultime notizie
New partnership gives Cartesian Therapeutics another shot at autoimmune disease market - MSN
RNAC Q1 2026 Earnings: Disappointing EPS Miss Yet Stock Surges 18%Earnings Weakness Phase - newsline.com
Cartesian Therapeutics Announces New Employment Inducement Grant - The Manila Times
New hire at Cartesian gets 6,100 stock options vesting to 2030 - Stock Titan
Cartesian climbs on licensing deal with WestGene for CAR-T therapies - MSN
RNAC: Directors elected and all proposals passed with strong support; no stockholder questions submitted - TradingView
Cartesian Therapeutics, Inc. (RNAC) soars 10.3%: Is further upside left in the stock? - MSN
Cartesian Eyes Multiple 2026-2027 Readouts As Descartes-08 Advances Toward Potential BLA - RTTNews
RNAC Reiterated by Wedbush -- Price Target Maintained at $38.00 - GuruFocus
RNAC Reiterated by BTIG -- Price Target Maintained at $44.00 - GuruFocus
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Announces Target Price $40 - Moomoo
Morgan Stanley Smith Barney (RNAC) lists exercises, vesting and a 3,924-share resale - Stock Titan
RNAC Reiterated by Needham -- Price Target Maintained at $40 - GuruFocus
Cartesian Therapeutics (RNAC) Shares Surge 30% on Licensing Agre - GuruFocus
WestGene Biopharma to collaborate with Cartesian Therapeutics on in vivo CAR-T for autoimmune disease - Traders Union
Why Is Cartesian Therapeutics Stock Trading Higher Today?Cartesian Therapeutics (NASDAQ:RNAC) - Benzinga
Cartesian partners with WestGene for in vivo autoimmune CAR-T - grafa.com
Cartesian inks licensing deal with WestGene (RNAC:NASDAQ) - Seeking Alpha
Cartesian Therapeutics stock jumps on WestGene partnership deal - Investing.com UK
Cartesian Therapeutics stock jumps on WestGene partnership deal By Investing.com - Investing.com Australia
Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance - TipRanks
Cartesian strikes licensing agreement with WestGene - The Pharma Letter
Cartesian Therapeutics (RNAC) licenses in vivo CAR-T delivery tech from WestGene - Stock Titan
Cartesian Therapeutics Announces Strategic Licensing Agreement With Westgene Biopharma To Accelerate The Development Of In Vivo Car-T Platform In Autoimmune Diseases - TradingView
Experimental in vivo CAR-T for myasthenia gravis could skip lab manufacturing - Stock Titan
Cartesian Therapeutics (RNAC) Slides 10.8% as Stock Tests Key Support LevelsVol Target Rebalance - newsline.com
Cartesian Therapeutics (RNAC) Faces Sharp Decline, Testing Key Support LevelsADD Alert - newsline.com
[144] Cartesian Therapeutics, Inc. SEC Filing - Stock Titan
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Cartesian Therapeutics (RNAC) Rises 3.33% as Stock Holds Above Key SupportHedge Fund Exposure - The Legal Advocate
Cartesian Therapeutics (RNAC) Gains 4.6% as Biotech Sector Shows Renewed InterestInstitutional Sentiment - The Legal Advocate
H.C. Wainwright Keeps Their Buy Rating on Cartesian Therapeutics (RNAC) - The Globe and Mail
Cartesian Therapeutics secures up to $150 million financing - The Pharma Letter
Cartesian Therapeutics (RNAC) Secures $150M Credit Facility for Growth Initiatives - GuruFocus
RNAC Maintained by Needham -- Price Target Lowered to $40.00 - GuruFocus
Cartesian Therapeutics stock price target maintained at $40 by Mizuho - Investing.com
Cartesian Therapeutics secures $150M non-dilutive financing, advancing CAR-T trials with key data expected in 2027. - Pluang
Cartesian Therapeutics Secures $150 Million Loan Agreement with K2 HealthVentures and Ankura Trust Company - Minichart
Cartesian Therapeutics Secures Up to $150 Million Credit Facility From K2 HealthVentures - marketscreener.com
Cartesian Therapeutics Lands Up to $150 Million in Non-Dilutive Financing to Support CAR-T Commercialization Push - citybiz
Cartesian Therapeutics IncEnters loan and security agreement on May 22SEC filing - marketscreener.com
Cartesian Secures Major Loan Facility to Extend Runway - TipRanks
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027 - The Manila Times
Milos Miljkovic to Depart Cartesian Therapeutic as Chief Medical Officer; Separation Agreement Expected - TradingView
Cartesian Therapeutics secures up to 150 million dollar credit facility to extend cash runway to 2028 - Traders Union
Cartesian Therapeutics (NASDAQ: RNAC) adds $150M credit line and extends cash runway - Stock Titan
Cartesian Therapeutics Secures up to $150 Million of - GlobeNewswire
Cartesian Therapeutics Inc. (RNAC) Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Loss, Stock Ticks HigherDividend Cut Risk - The Legal Advocate
Cartesian Therapeutics (RNAC) Q1 2026 Earnings Miss: Breaking Down the NumbersEarnings Revision Upgrade - Newser
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):